Low-dose naltrexone as a treatment for chronic fatigue syndrome

Bolton, Monica Jane, Chapman, Bryan Paul and Van Marwijk, Harm (2020) Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Reports, 13. a232502 1-5. ISSN 1757-790X

[img] PDF - Accepted Version
Available under License Creative Commons Attribution-Non-Commercial.

Download (378kB)
[img] PDF - Published Version
Available under License Creative Commons Attribution-Non-Commercial.

Download (226kB)

Abstract

Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn’s disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, postexertional malaise, pain and autonomic and neurocognitive disturbances. This series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome shows the range of responses they observed when taking LDN, from life changing to a reduction in some symptoms only. Treatment doses ranged from 4 to 12 mg. Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available.

Item Type: Article
Keywords: drugs and medicines, general practice/family medicine, Adult, Fatigue Syndrome, Chronic, Female, Humans, Male, Middle Aged, Naltrexone, Off-Label Use
Schools and Departments: Brighton and Sussex Medical School > Primary Care and Public Health
SWORD Depositor: Mx Elements Account
Depositing User: Mx Elements Account
Date Deposited: 29 Sep 2021 07:07
Last Modified: 29 Sep 2021 07:15
URI: http://sro.sussex.ac.uk/id/eprint/101960

View download statistics for this item

📧 Request an update